New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Tilray Brands, Inc.
TLRY
Shape
US Flag

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

2B

Drug Manufacturers - Specialty & Generic

Next Earning date - 14 Jan 2025

2B

Drug Manufacturers - Specialty & Generic

Next Earning date - 14 Jan 2025

1.69USD
Shape0.05 ( 3.05%)
favorite-chart

Relative Strenght

52
favorite-chart

Volume Buzz

19%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

43%

Quote Panel

Shape
Updated October 27, 2024
1W 6.96 % 1M -3.98 % 3M -7.65 % 1Y -2.31 %

Key Metrics

Shape
  • Market Cap

    1.53B


  • Shares Outstanding

    903.29M


  • Share in Float

    897.06M


  • Dividende

    0


  • Earning Date

    14 Jan 2025


  • Price Target

    1.69


  • Average Volume

    23.62M


  • Beta

    2.189


  • Range

    1.45-2.97


  • Industry

    Drug Manufacturers - Specialty & Generic


  • Website

    https://www.tilray.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

1.88x

P/S Ratio

0.39x

P/B Ratio

0.1

Debt/Equity

-25.6%

Net Margin

$-0.3

EPS

How TLRY compares to sector?

P/E Ratio

Relative Strength

Shape

TLRY

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$907M

Shape353%

2025-Revenue

$0.16

Shape-265%

2025-EPS

$89M

Shape344%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Canaccord Genuity

upgrade

Previous: Not converted

2022-03-05

Now: Buy

Cantor Fitzgerald

upgrade

Previous: Not converted

2021-06-10

Now: Overweight

Jefferies

upgrade

Previous: Not converted

2021-05-09

Now: Market Outperform

Earnings GrowthShape

status-upYoY

Current

Estimates

Q4.22

arrow
arrow

N/A

-0.06
vs 0.01

Q1.23

arrow
arrow

N/A

-0.04
vs 0.04

Q2.23

arrow
arrow

N/A

-0.15
vs -0.34

Q3.23

arrow
arrow

N/A

-0.10
vs -0.08

Q4.23

arrow
arrow

N/A

-0.05
vs -0.06

Q1.24

arrow
arrow

N/A

-0.12
vs -0.04

Q2.24

arrow
arrow

N/A

-0.04
vs -0.15

Q3.24

arrow
arrow

N/A

-0.04
vs -0.10

Q4.24

arrow
arrow

N/A

-0.05
vs -0.05

Q1.25

arrow
arrow

N/A

-0.05
vs -0.12

Sales GrowthShape

status-upYoY

Current

Estimates

Q4.22

arrow
arrow

-7%

144.1M  vs 155.2M

Q1.23

arrow
arrow

-4%

145.6M  vs 151.9M

Q2.23

arrow
arrow

+20%

184.2M  vs 153.3M

Q3.23

arrow
arrow

+15%

176.9M  vs 153.2M

Q4.23

arrow
arrow

+34%

193.8M  vs 144.1M

Q1.24

arrow
arrow

+29%

188.3M  vs 145.6M

Q2.24

arrow
arrow

+25%

229.9M  vs 184.2M

Q3.24

arrow
arrow

+13%

200M  vs 176.9M

Q4.24

arrow
arrow

+13%

218.2M  vs 193.8M

Q1.25

arrow
arrow

+16%

218.9M  vs 188.3M

Return on EquityShape

status-upQoQ

Q4.22

arrow
arrow

-1%

-0.01
vs -0.01

Q1.23

arrow
arrow

-35%

-0.35
vs -0.01

Q2.23

arrow
arrow

-4%

-0.04
vs -0.35

Q3.23

arrow
arrow

-2%

-0.02
vs -0.04

Q4.23

arrow
arrow

-1%

-0.01
vs -0.02

Q1.24

arrow
arrow

-3%

-0.03
vs -0.01

Q2.24

arrow
arrow

-1%

-0.01
vs -0.03

Q3.24

arrow
arrow

-1%

-0.01
vs -0.01

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

343

343
vs 348

-1%

Q4.22

arrow
arrow

387

387
vs 343

13%

Q1.23

arrow
arrow

364

364
vs 387

-6%

Q2.23

arrow
arrow

356

356
vs 364

-2%

Q3.23

arrow
arrow

376

376
vs 356

6%

Q4.23

arrow
arrow

375

375
vs 376

0%

Q1.24

arrow
arrow

377

377
vs 375

1%

Q2.24

arrow
arrow

367

367
vs 377

-3%

Earnings Growth

Latest News